The predominant focus of the AiM Institute is discovering precision medicine therapeutics for the subset of dementia patients with immune-driven pathology: i.e., immunodementia. We have a series of programs in our discovery pipeline targeting mechanisms for immunodementia validated by human genetics, and have established cutting-edge expertise and technologies enabling us to be at the forefront of delivering medicines within this niche.
Large-scale evidence from human genetics highlight immune and inflammation mediated mechanisms as potentially causing dementia. Targeting immune dysfunction and enhancing internal neuroimmune mechanisms may provide a viable approach, therefore, to treat and prevent dementia.
Focusing on such mechanisms may also yield next generation treatments for dementia that are complementary to treatments currently in development that target A-beta and tau. Moreover, advances in translational sciences indicate potentially viable ways to identify patients most likely to benefit from targeting neuroimmunity and neuroinflammation, including non-invasive translational biomarkers.
The AiM Institute is building on its strengths and expertise in immune cell biology, genomics and small molecules to deliver novel precision immunotherapies targeting myeloid lineage cells. One such therapy, E7046, is a first-in-class orally active EP4 receptor antagonist currently under clinical development.
Advances in immunotherapies and precision medicines that harness the power of the immune system have given oncology patients new hope in the fight against cancer. Considerable unmet need remains, however, in this rapidly evolving field, especially for patients who do not respond to the immunotherapies currently available.
The tumor and its microenvironment are interdependent, with both defining the extent of immune tolerance, growth and evolution. Targeting the tumor microenvironment, therefore, has emerged as a viable way to prevent tumor growth and achieve remission. Within the tumor immune microenvironment, cells from myeloid lineage are among the most abundant and have been demonstrated to have a distinct role in tumor biology from other immune cells targeted by current immunotherapies (including T-cells).
The AiM Institute also has discovery programs in auto-immune and related diseases that build upon our expertise in targeting toll-like receptors and prostaglandins. We are prosecuting genetically validated therapeutic targets within this area, including for systemic lupus erythematosus.